The authors of the published paper [
1] would like to correct
Table 1. The sixth row in the second column should have been Amphotericin B Lipid Complex (ABLC). Therefore,
Table 1 should read as follows:
Table 1.
Treatment recommendations for invasive aspergillosis.
We apologize for any inconvenience caused to readers. The manuscript will be updated and the original will remain available on the article webpage.
Conflicts of Interest
The authors declare no conflict of interest.
Reference
- Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25. [Google Scholar] [CrossRef]
Table 1.
Treatment recommendations for invasive aspergillosis.
| Recommendation | Drug | Dosing | Comments |
|---|
| Primary | Voriconazole | 6 mg/kg IV every 12 h times two then 4 mg/kg IV every 12 h | Oral therapy at mg/kg dosing or 200–300 mg every 12 h; TDM required |
| Alternatives | Lipsosomal amphotericin B (L-AMB) | 3–5 mg/kg/day IV | |
| | Isavuconazole | 200 mg every 8 h IV or PO times six then 200 mg daily IV or PO | Need for TDM remains undefined |
| | Voriconazole plus Anidulafungin | Vorizonazole as above plus Anidulafungin 200 mg IV daily times one then 100 mg IV daily | Combination therapy considered in severe disease and with hematologic malignancy |
| | Amphotericin B Lipid Complex (ABLC) | 5 mg/kg/day IV | |
| Secondary | Caspofungin | 70 mg IV daily times one then 50 mg IV daily | Monotherapy as salvage |
| | Posaconazole | Oral suspension: 200 mg PO every 8 h, Tablet: 300 mg PO every 12 h times two then 300 mg PO daily, Intravenous: 300 mg IV every 12 h times two then 300 mg IV daily | Caution in use of tablet formulation with acid suppression; TDM required |
| | Itraconazole | 200 mg PO every 12 h | TDM required |
© 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license ( http://creativecommons.org/licenses/by/4.0/).
